PERISPA Eperisone Hydrochloride 50mg Tablet 1's
RXDRUG-DR-XY35442-1pc
- View all variations as list
| CODE | Dosage Strength | Drug Packaging | Availability | Price | ||
|---|---|---|---|---|---|---|
|
RXDRUG-DR-XY35442-1pc
|
In stock
|
₱2200 |
Discreet Packaging
We recognize that purchasing medications can be a deeply personal matter. To respect your privacy, we ensure that all orders are packaged discreetly, with no indication of the contents on the packaging. This means that even our couriers remain unaware of the package contents.
Furthermore, we uphold strict confidentiality standards. We guarantee that your order information will never be disclosed to any third party. Your trust is paramount to us, and we are committed to safeguarding your privacy at every step of the process. Our dedication to discretion and confidentiality is part of our unwavering commitment to you, our valued customer.
FDA-registered Products
FDA-licensed Pharmacies
Sellers of this product
Features
Brand
Perispa
Full Details
Dosage Strength
50 mg
Drug Ingredients
- Eperisone
Drug Packaging
Tablet 1's
Generic Name
Eperisone Hydrochloride
Dosage Form
Tablet
Registration Number
DR-XY35442
Drug Classification
Prescription Drug (RX)
Description
Indications/Uses
Spastic paralysis in the following diseases: Cerebrovascular disease, spastic spinal paralysis, cervical spondylosis, postoperative sequelae (including cerebrospinal tumor), sequelae to trauma (spinal trauma, head injury), amyotrophic lateral sclerosis, cerebral palsy, spinocerebellar degeneration, spinal vascular diseases & other encephalomyelopathies.
Improvement of muscular hypertonic symptoms in the following diseases: Cervical syndrome, periarthritis of the shoulder, lumbago.
Improvement of muscular hypertonic symptoms in the following diseases: Cervical syndrome, periarthritis of the shoulder, lumbago.
Dosage/Direction for Use
The usual adult dosage for oral use is one tablet three times a day after each meal or as directed by the physician. The dosage should be adjusted depending on the patient's age and severity of symptoms.
Administration
Should be taken with food: Take after each main meal.
Contraindications
Patients with a history of hypersensitivity to any ingredients of the drug.
Special Precautions
Careful administration (Eperisone HCl should be administered with care in the following patients): Patients with a history of drug hypersensitivity.
Patients with hepatic function disorder.
Important precautions: weakness, light-headedness, sleepiness or other symptoms may occur. In the event of such symptoms, the dosage should be reduced or treatment discontinued. Patients should be cautioned against engaging in potentially hazardous activities requiring alertness, such as operating machinery or driving a car.
Use in Children: Safe use of Eperisone hydrochloride (Perispa) in children has not been definitely established.
Use in Elderly: Since the elderly patients often have a psychological hypofunction, it is advisable to take measures, such as reduction in dosage under careful supervision.
Patients with hepatic function disorder.
Important precautions: weakness, light-headedness, sleepiness or other symptoms may occur. In the event of such symptoms, the dosage should be reduced or treatment discontinued. Patients should be cautioned against engaging in potentially hazardous activities requiring alertness, such as operating machinery or driving a car.
Use in Children: Safe use of Eperisone hydrochloride (Perispa) in children has not been definitely established.
Use in Elderly: Since the elderly patients often have a psychological hypofunction, it is advisable to take measures, such as reduction in dosage under careful supervision.
Use In Pregnancy & Lactation
Safety for use in pregnancy has not been established. Eperisone HCl (Perispa) should only be used in pregnant women or women suspected of being pregnant if therapeutic benefits are evaluated to outweigh the possible risk of treatment.
It is recommended that this drug not be used during lactation. If it must be used at such times, the patients should discontinue breast-feeding during treatment
It is recommended that this drug not be used during lactation. If it must be used at such times, the patients should discontinue breast-feeding during treatment
Adverse Reactions
Excessive relaxation, stomachache, nausea, vertigo, anorexia, drowsiness, skin rashes, diarrhea, indigestion. GI disturbances, insomnia, headache & constipation.
Drug Interactions
There is a report that disturbances in ocular accommodation occurred after the concomitant use of tolperisone hydrochloride and methocarbamol.
Storage
Store at temperatures not exceeding 30°C in dry place. Protect from light.
Action
Pharmacology: Skeletal muscle relaxation, relaxation of hypertonic skeletal muscles, improves intramuscular blood flow, suppression of spinal reflex potentials, reduction of muscle spindle sensitivity via motor neurons, vasodilatation and augmentation of blood flow, analgesic action and inhibition of the pain reflex in the spinal cord.
Efficacy: Data based on the assessment of 8660 clinical reports of Eperisone hydrochloride (Perispa) usage - Oct. 1982 to Sept, 1986.
Symptom Rate of Improvement (%): Rigidity 70.2, Stiffness 70.4, Dizziness 77.4, Headache 78.9, Tinnitus 65.9, Cervical pain 71.6, Stiff shoulder 82.1, Lumbago 74.8, Difficulty in going up & downstairs 55.2, Difficulty in walking 56.5.
Pharmacokinetics: The pharmacokinetic properties of Eperisone hydrochloride (Perispa) after a single dose of 150 mg/day orally for 14 consequent days to 8 healthy adult male volunteers: Tmax: 1.6 to 1.9 hr.
Cmax: 7.5 to 7.9 ng/ml.
Elimination half life: 1.6 to 1.8 hr.
Area under the plasma concentration time curve (AUC): 19.7 to 21.1 ng.hr/ml.
The plasma concentration profiles of Eperisone hydrochloride (Perispa) determined at day 8 and day 14 did not significantly vary from those of the first day.
Efficacy: Data based on the assessment of 8660 clinical reports of Eperisone hydrochloride (Perispa) usage - Oct. 1982 to Sept, 1986.
Symptom Rate of Improvement (%): Rigidity 70.2, Stiffness 70.4, Dizziness 77.4, Headache 78.9, Tinnitus 65.9, Cervical pain 71.6, Stiff shoulder 82.1, Lumbago 74.8, Difficulty in going up & downstairs 55.2, Difficulty in walking 56.5.
Pharmacokinetics: The pharmacokinetic properties of Eperisone hydrochloride (Perispa) after a single dose of 150 mg/day orally for 14 consequent days to 8 healthy adult male volunteers: Tmax: 1.6 to 1.9 hr.
Cmax: 7.5 to 7.9 ng/ml.
Elimination half life: 1.6 to 1.8 hr.
Area under the plasma concentration time curve (AUC): 19.7 to 21.1 ng.hr/ml.
The plasma concentration profiles of Eperisone hydrochloride (Perispa) determined at day 8 and day 14 did not significantly vary from those of the first day.
MedsGo Class
Muscle Relaxants
Please sign in so that we can notify you about a reply